NERV - Minerva Neurosciences, Inc.
| Previous Close | 8.40 |
| Open | 8.40 |
| Bid | 8.20 x 1200 |
| Ask | 8.30 x 800 |
| Day's Range | 8.20 - 8.50 |
| 52 Week Range | 4.80 - 9.25 |
| Volume | 82,894 |
| Avg. Volume | 173,460 |
| Market Cap | 321.827M |
| Beta | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•13 days ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•3 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
- Zacks•5 months ago
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT
Q4 2017 Minerva Neurosciences Inc Earnings Call
- Associated Press•5 months ago
Minerva Neurosciences posts 4Q profit
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
- Zacks•8 months ago
Minerva Initiates Phase III Study on Schizophrenia Candidate
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
- Thomson Reuters StreetEvents•9 months ago
Edited Transcript of NERV earnings conference call or presentation 6-Nov-17 1:30pm GMT
Q3 2017 Minerva Neurosciences Inc Earnings Call
- Simply Wall St.•11 months ago
Is Minerva Neurosciences Inc (NERV) Undervalued?
Minerva Neurosciences Inc (NASDAQ:NERV), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Minerva Neurosciences What’s the opportunity in NERV? Great newsRead More...
- Zacks•last year
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
- TheStreet.com•last year
Adamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers
The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.
